首页> 外文期刊>PACE: Pacing and clinical electrophysiology >Proportion of patients with implanted permanent pacemakers with atrial fibrillation receiving appropriate medical prophylaxis in North Wales
【24h】

Proportion of patients with implanted permanent pacemakers with atrial fibrillation receiving appropriate medical prophylaxis in North Wales

机译:在北威尔士接受永久性心脏起搏器植入的永久性起搏器的患者接受适当的医学预防的比例

获取原文
获取原文并翻译 | 示例
       

摘要

Background: Atrial fibrillation (AF) is associated with an increased long-term risk of stroke, heart failure, and mortality. Previous studies have demonstrated the suboptimal use of anticoagulation therapy in patients with AF. Methods: A retrospective survey of patients (N = 1,113) fitted with dual-chamber pacemakers found 71 patients (age 69 ± 35, mean ± standard deviation) with atrial tachycardia and AF (defined as 5 minutes per day). Their medical records and anticoagulation status were investigated and used to stratify each patient for stroke risk with the Birmingham 2009 schema (CHA 2DS 2-VASc) and assessed to determine the rate of appropriate thromboembolism (TE) prophylaxis prescription. Results: The most common overall concomitant risk factor for stroke was hypertension (54%), followed by age ≥75 (51%), being female and previous stroke/transient ischemic attack/TE (39%). The average CHA 2DS 2-VASc score was 3.7 ± 1.6. Fifty-six percent of the patients were not receiving appropriate anticoagulation therapy. Conclusion: This study demonstrates an underutilization of the oral anticoagulant warfarin in patients with known AF and that the clinicians may not be regarding current stroke risk factors when adopting a thromboprophylaxis strategy. (PACE 2012; 35:935-942)
机译:背景:房颤(AF)与中风,心力衰竭和死亡率的长期风险增加相关。先前的研究表明房颤患者抗凝治疗的最佳选择。方法:对装有双腔起搏器的患者(N = 1,113)进行回顾性调查,发现71名患者(年龄69±35,平均值±标准差)患有房性心动过速和AF(定义为每天> 5分钟)。对他们的病历和抗凝状态进行了调查,并使用伯明翰2009方案(CHA 2DS 2-VASc)将每位患者的中风风险分层,并进行评估以确定适当的血栓栓塞(TE)预防处方的比率。结果:中风最常见的总体伴随危险因素是高血压(54%),其次是年龄≥75岁(51%),是女性和既往中风/短暂性脑缺血发作/ TE(39%)。 CHA 2DS 2-VASc的平均得分是3.7±1.6。 56%的患者未接受适当的抗凝治疗。结论:这项研究表明已知房颤患者口服抗凝华法林的利用不足,并且临床医生在采取血栓预防策略时可能不会考虑当前的中风危险因素。 (PACE 2012; 35:935-942)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号